Nanobiotix: well oriented on broker's comments

(CercleFinance.com) - Nanobiotix is up nearly 3%, buoyed by comments from Stifel, which is initiating coverage with a 'buy' recommendation and a price target of €16, on the shares of the nanomedicine biotech company.


NBTXR3, Nanobiotix's most advanced asset, is an innovative radioenhancer designed to improve the efficacy of radiotherapy", explains the broker, also pointing out that the company is already planning to explore all facets of nanoparticles.

Copyright (c) 2024 CercleFinance.com. All rights reserved.